000088209512/31false00008820952024-05-082024-05-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 8, 2024
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware0-1973194-3047598
(State or Other Jurisdiction of Incorporation)(Commission File No.)(IRS Employer Identification No.)


333 Lakeside Drive, Foster City, California
(Address of principal executive offices)
94404
(Zip Code)
650-574-3000
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value, $0.001 per shareGILDThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



Item 5.03    Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On February 1, 2024, the Board of Directors (the “Board”) of Gilead Sciences, Inc. (the “Company”) adopted amendments to the Company’s Restated Certificate of Incorporation (the “Amendment”) to reflect new Delaware law provisions regarding officer exculpation under Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”). On May 8, 2024, the Company’s stockholders approved the Amendment at the Company’s 2024 annual meeting of stockholders (the “Annual Meeting”). The Amendment is attached to this Current Report on Form 8-K as Exhibit 3.1. On the same day, the Board adopted a restatement of the Company’s Restated Certificate of Incorporation (the “Restated Charter”), which incorporates the provisions included in the Amendment. The Restated Charter is attached to this Current Report on Form 8-K as Exhibit 3.2 and is incorporated by reference herein.
Item 5.07    Submission of Matters to a Vote of Security Holders.
The Annual Meeting was held on May 8, 2024. Of the 1,246,969,303 shares of the Company’s common stock entitled to vote at the Annual Meeting, 1,115,379,536 shares were represented at the beginning of the meeting in person or by proxy, which constituted a quorum. The voting results are presented below.
The Company’s stockholders elected nine directors to serve for the next year and until their successors are elected and qualified. The votes regarding the election of directors were as follows:
NameVotes ForVotes AgainstAbstentionsBroker Non-Votes
Jacqueline K. Barton, Ph.D.995,391,975 12,399,781 1,373,568 106,243,270 
Jeffrey A. Bluestone, Ph.D.1,000,314,606 7,419,797 1,430,921 106,243,270 
Sandra J. Horning, M.D.985,486,994 22,304,826 1,373,504 106,243,270 
Kelly A. Kramer980,895,123 26,851,069 1,419,132 106,243,270 
Ted W. Love, M.D.1,002,644,132 5,021,345 1,499,847 106,243,270 
Harish Manwani968,115,418 39,518,665 1,531,241 106,243,270 
Daniel P. O’Day939,111,309 63,134,940 6,919,075 106,243,270 
Javier J. Rodriguez1,000,194,729 7,506,046 1,464,549 106,243,270 
Anthony Welters932,173,164 75,508,127 1,484,033 106,243,270 
The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposal received the following votes:
Votes For1,039,381,050 
Votes Against74,100,517 
Abstentions1,927,027 
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:
Votes For928,702,915 
Votes Against78,647,808 
Abstentions1,814,601 
Broker Non-Votes106,243,270 
The Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. The proposal received the following votes:
Vote For905,468,022 
Vote Against101,692,634 
Abstentions2,004,668 
Broker Non-Votes 106,243,270 



The Company’s stockholders did not approve a stockholder proposal requesting that the Board include one member from the Company’s non-management employees. The proposal received the following votes:
Votes For59,235,065 
Votes Against946,161,838 
Abstentions3,768,421 
Broker Non-Votes106,243,270 
The Company’s stockholders did not approve a stockholder proposal requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response to state policies regulating abortion, and detailing any strategies beyond litigation and legal compliance that the Company may deploy to minimize or mitigate these risks. The proposal received the following votes:
Votes For17,930,954 
Votes Against977,168,730 
Abstentions14,065,640 
Broker Non-Votes106,243,270 
The Company’s stockholders did not approve a stockholder proposal requesting that the Board adopt a policy requiring the Company’s named executive officers to retain at least 25% of net-after tax shares of stock acquired through equity pay programs until reaching normal retirement age (at least age 60). The proposal received the following votes:
Votes For361,356,676 
Votes Against645,764,310 
Abstentions2,044,338 
Broker Non-Votes106,243,270 
Item 9.01    Financial Statements and Exhibits.
(d)    Exhibits
Exhibit NumberDescription
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GILEAD SCIENCES, INC.
(Registrant)
/s/ DEBORAH H. TELMAN
Deborah H. Telman
EVP, Corporate Affairs, General Counsel and Corporate Secretary

Date: May 9, 2024